Department of Urology, AZ Maria Middelares, Ghent, Belgium.
Belgian Cancer Registry, Brussels, Belgium.
Pathol Oncol Res. 2020 Oct;26(4):2605-2612. doi: 10.1007/s12253-020-00860-w. Epub 2020 Jul 6.
To determine whether Gleason scores were concordant between prostate biopsies (bGS) and the definitive resection specimen (pGS) excised with robot-assisted radical prostatectomy (RARP); to identify clinical and pathological factors that might predict upgrading; and to evaluate how upgrading affected outcome. Between 2009 and 2016, 25 Belgian centers participated in collecting prospective data for patients that underwent RARP. We analyzed the concordance rate between the bGS and the pGS in 8021 patients with kappa statistics, and we compared concordance rates from different centers. We assessed the effect of several clinical and pathological factors on the concordance rate with logistic regression analysis. The concordance rate for the entire population was 62.9%. Upgrading from bGS to pGS occurred in 27.3% of patients. The number of biopsies was significantly associated with concordance. Older age (>60 y), a higher clinical T stage (≥cT2), a higher PSA value at the time of biopsy (>10 ng/ml), and more time between the biopsy and the radical prostatectomy were significantly associated with a higher risk of upgrading. Positive margins and PSA relapse occurred more frequently in upgraded patients. Center size did not significantly affect the concordance rate (p = 0.40).This prospective, nationwide analysis demonstrated a Gleason score concordance rate of 62.9%. Upgrading was most frequently observed in the non-concordant group. We identified clinical and pathological factors associated with (non)-concordance. Upgrading was associated with a worse oncological outcome. Center volume was not associated with pathological accuracy.
为了确定前列腺活检(bGS)和机器人辅助根治性前列腺切除术(RARP)切除的明确标本(pGS)之间的 Gleason 评分是否一致;确定可能预测升级的临床和病理因素;并评估升级如何影响结果。2009 年至 2016 年期间,25 个比利时中心参与收集接受 RARP 治疗的患者的前瞻性数据。我们使用 Kappa 统计数据分析了 8021 例患者的 bGS 和 pGS 之间的一致性率,并比较了来自不同中心的一致性率。我们使用逻辑回归分析评估了几个临床和病理因素对一致性率的影响。整个人群的一致性率为 62.9%。bGS 到 pGS 的升级发生在 27.3%的患者中。活检次数与一致性显著相关。年龄较大(>60 岁)、临床 T 期较高(≥cT2)、活检时 PSA 值较高(>10ng/ml)以及活检与根治性前列腺切除术之间的时间间隔较长与升级的风险增加显著相关。升级患者中更常出现阳性切缘和 PSA 复发。中心规模对一致性率无显著影响(p=0.40)。这项前瞻性、全国性分析显示 Gleason 评分一致性率为 62.9%。升级最常发生在不一致组中。我们确定了与(非)一致性相关的临床和病理因素。升级与较差的肿瘤学结果相关。中心容量与病理准确性无关。